Biocartis SA

on . Posted in SME

BiocartisBiocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics and immunodiagnostics solutions. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients. The Molecular Diagnostics Platform Idylla™ is tailored to the molecular diagnostics market and designed to measure multiple DNA or RNA-based biomarkers in a wide variety of patient sample types. The Multiplex Biomarker Analysis Platform Evalution™ is tailored to the clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers, delivering superior data quality and rapid results.

Evalution™ allows users to perform bioassays far more quickly and cost-effectively. It drastically reduces hands-on-time and development complexity, thereby speeding up biomarker verification and validation. The advanced semi-conductor technologies and microfluidics provide fast and reliable detection and quantification. A 40-micron binary-coded silicon microparticle is the new foundation for biomarker analysis. Thousands of different digital codes can be generated. Non-fading and discrete, these digitally coded microparticles are your key to biomarker analysis. These microparticles can typically be coated with any protein or nucleic acid to serve as a capture probe. The microfluidic architecture and fast reaction kinetics yield better specificity and high reproducibility, and delivers sensitivity for both protein and nucleic-acid testing. Real-time and end-point measurements are possible, providing fast quantification and an extended dynamic range through kinetic measurement. Optimized binding chemistry provides fast and flexible detection and quantification of both nucleic-acid and protein-based biomarkers. Potential user applications include drug/biomarker discovery, protein/genetic expression profiling and characterization of receptor-ligand interactions.

BiocartisEvalution™ instrument and cartridge (left) and microparticles in a microfluidic channel (right).

Due to its simple protocols and flexibility in biomarker panel building the Evalution™ platform is very well suited for the multiplex miRNA expression profiling in the EU-FP7 BiomarCaRe project. To this end Biocartis develops a completely new application to be transferred to the University Clinic Hamburg-Eppendorf that will be used on a case cohort of 20k patient samples to evaluate the strength of these combined biomarkers for Cardiovascular Risk Assessment.